Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on May 26, 2016. The filing discloses amendments to employment agreements for the Chief Executive Officer and Chief Financial Officer, as well as a new employment agreement for the Vice President of Commercial Operations. These changes were approved by the Board of Directors following a recommendation from the Compensation Committee, which engaged Arthur J. Gallagher & Co. to assist with compensation analysis.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements.
Material Changes
The filing details significant changes to executive compensation packages effective May 26, 2016:
- CEO (Jeffrey A. Duchemin):
- Severance for termination without Cause increased from 12 to 18 months of base salary.
- COBRA coverage for termination without Cause increased from 12 to 18 months.
- Severance for Change in Control increased from 18 to 24 months of base salary.
- COBRA coverage for Change in Control increased from 18 to 24 months.
- A "net best or better-off" cutback provision was added to mitigate excise taxes under Section 4999.
- CFO (Robert E. Gagnon):
- Maximum annual cash incentive compensation increased from 50% to 100% of base salary.
- Severance for Change in Control increased from 12 to 18 months of base salary.
- COBRA coverage for Change in Control increased from 12 to 18 months.
- A "net best or better-off" cutback provision was added.
- VP Commercial Operations (Yong Sun):
- New agreement with an initial term expiring August 26, 2017, with automatic one-year extensions.
- Annual base salary set at $244,000.
- Annual cash incentive eligibility up to 35% of base salary.
- Severance for termination without Cause set at 6 months of base salary paid over one year.
- Severance for Change in Control set at 12 months of base salary in a lump sum, with immediate acceleration of stock options.
- Includes a one-year non-compete and non-solicit covenant.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary on business operations. The primary risk disclosed relates to the increased potential liability for severance payments and the acceleration of equity awards in the event of a Change in Control or termination without Cause. The inclusion of "net best or better-off" provisions indicates management's intent to manage potential excise tax liabilities associated with golden parachute payments.
Investor Verification Checklist
- Verify the total potential cash liability for severance payments under the new terms for the CEO, CFO, and VP.
- Review the specific definitions of "Cause" and "Change in Control" in the attached Exhibits 10.1, 10.2, and 10.3.
- Assess the impact of the increased incentive compensation targets on future cash flow requirements.
- Confirm the status of stock option acceleration clauses for the VP in the event of a Change in Control.